Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Iovance Biotherapeutics Inc IOVA

Healthcare Biotechnology
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously... see more

Recent & Breaking News (NDAQ:IOVA)

Iovance Biotherapeutics to Present Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at American Association for Cancer Research (AACR) 2021 Annual Meeting

GlobeNewswire March 10, 2021

Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences

GlobeNewswire March 1, 2021

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates

GlobeNewswire February 25, 2021

Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25, 2021

GlobeNewswire February 18, 2021

Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences

GlobeNewswire January 19, 2021

Iovance Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021

GlobeNewswire December 28, 2020

Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer

GlobeNewswire December 14, 2020

Iovance Biotherapeutics to Present at Upcoming Conferences in December

GlobeNewswire November 30, 2020

Iovance Biotherapeutics Presents Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting

GlobeNewswire November 9, 2020

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2020 Financial Results and Corporate Updates

GlobeNewswire November 5, 2020

Iovance Biotherapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5, 2020

GlobeNewswire October 30, 2020

Iovance Biotherapeutics to Present at Upcoming Conferences in November

GlobeNewswire October 28, 2020

Bragar Eagel & Squire, P.C. Is Investigating Evolus, Lizhi, Iovance Biotherapeutics, and Y-mAbs Therapeutics and Encourages Investors to Contact the Firm

GlobeNewswire October 9, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

PR Newswire October 8, 2020

Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Iovance Biotherapeutics, Inc. (IOVA) Investigation

ACCESSWIRE IA October 8, 2020

Iovance Biotherapeutics to Present at Upcoming October Conferences

GlobeNewswire October 6, 2020

Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma

GlobeNewswire October 5, 2020

Iovance Biotherapeutics to Present at BTIG Biotechnology Conference 2020

GlobeNewswire August 7, 2020

Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update

GlobeNewswire August 6, 2020

Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001

GlobeNewswire August 6, 2020